Role of molecular biology in the management of pancreatic cancer.

Authors :: Boileve A
Smolenschi C
Lambert A
Boige V
Tarabay A
Valery M
Fuerea A
Pudlarz T
Conroy T
Hollebecque A
Ducreux M
Source :: World journal of gastrointestinal oncology [World J Gastrointest Oncol] 2024 Jul 15; Vol. 16 (7), pp. 2902-2914.
Publication Year :: 2024
Abstract: Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges in patient management due to a dismal prognosis, increasing incidence, and limited treatment options. In this regard, precision medicine, which personalizes treatments based on tumour molecular characteristics, has gained great interest. However, its widespread implementation is not fully endorsed in current recommendations. This review explores key molecular alterations in PDAC, while emphasizing differences between KRAS -mutated and KRAS -wild-type tumours. It assesses the practical application of precision medicine in clinical settings and outlines potential future directions with respect to PDAC. Actionable molecular targets are examined with the aim of enhancing our understanding of PDAC molecular biology. Insights from this analysis may contribute to a more refined and personalized approach to pancreatic cancer treatment, ultimately improving patient outcomes.<br />Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.<br /> (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.)